electroCore (ECOR) LD Micro Main Event XVI summary

Business performance and financials

• Achieved a five-year CAGR of 69% and expects $25 million+ in 2024 revenue with 85%-86% gross margins.

• Cash position is $14.5 million with no debt; clean capital structure with pre-funded warrants for institutional investors.

• Cash used in Q2 2024 was $1.8 million on $6.1 million revenue; expects to be cash positive and GAAP profitable early next year.

• Contribution margin for incremental revenue is 60%-65%, with variable costs modeled at 30%.

• Sequential revenue growth for seven consecutive quarters, with the eighth expected.

Product portfolio and technology

• Three main product lines: prescription gammaCore, Truvaga for wellness, and TAC-STIM for military applications.

• gammaCore is FDA-cleared for acute and preventive headache treatment, with strong clinical differentiation in migraine and cluster headache.

• Truvaga is a lower-dose, direct-to-consumer wellness device, growing at 200%-250% annually.

• TAC-STIM developed for the Air Force, with potential for civilian crossover; contracts are lumpy but offer future growth.

• Technology uses a proprietary modified sine wave for targeted, comfortable vagus nerve stimulation, distinct from TENS devices.

Market penetration and customer base

• Largest customer is the VA hospital system; therapy is free to patients, with 6,500 handsets dispensed and 10% facility penetration.

• NHS in the UK accounts for about 10% of revenue; Kaiser Healthcare System and regional Blues add to 40 million covered lives.

• Plans to leverage clinical data to approach national insurers and Medicare in 2025-2026.

• E-commerce storefront for Truvaga is rapidly expanding, with a return on ad spend of 3.25 in Q2.

• Amazon launch planned for early 2025; brick-and-mortar delayed until profitability is achieved.